Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC “Big Fat Lie” Settlements Half Complete; “Red Flag” Efforts March On

This article was originally published in The Tan Sheet

Executive Summary

FTC's settlement with the marketer of Himalayan Diet Breakthrough brings the commission to its half-way point in settling the six complaints filed against dietary supplement firms under "Operation Big Fat Lie.

You may also be interested in...



FTC Targets Herbal Remedies Marketed to Hispanics, Settles “Fat Lie” Suit

Latinos Group Promotions must notify consumers and resellers of its herbal supplement Arcomig and its powdered tea Essiac Formula that claims made for the products were false and unsupported, according to a stipulated judgment announced by the Federal Trade Commission July 26

FTC Targets Herbal Remedies Marketed to Hispanics, Settles “Fat Lie” Suit

Latinos Group Promotions must notify consumers and resellers of its herbal supplement Arcomig and its powdered tea Essiac Formula that claims made for the products were false and unsupported, according to a stipulated judgment announced by the Federal Trade Commission July 26

FTC Targets Herbal Remedies Marketed to Hispanics, Settles “Fat Lie” Suit

Latinos Group Promotions must notify consumers and resellers of its herbal supplement Arcomig and its powdered tea Essiac Formula that claims made for the products were false and unsupported, according to a stipulated judgment announced by the Federal Trade Commission July 26

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel